Takeda seals $1.2 billion oncology deal with Innovent Biologics
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes
The proposed transaction will be effected as a share swap
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
Building on the Merck Foundation’s longstanding commitment to advancing access to high-quality health care, new national initiative supports grants to 11 organizations across the country
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
Subscribe To Our Newsletter & Stay Updated